Clinical Studies – Targeting Acute and Chronic Thromboembolic Disorders
First Published, Prospective, International, Observational Study of a NOAC in NVAF Patients1
Objective
- Evaluate major bleeding and stroke or systemic embolism in NVAF patients in real world clinical settings, ranging from primary care practices to cardiologists’ offices and hospitals1
Study design
Population
- 6,784 adults with NVAF newly receiving once-daily Xarelto for prevention of stroke and systemic embolism for NVAF were followed for 1 year, or 30 days following permanent treatment discontinuation1
XANTUS: CHADS2-scores
AF, atrial fibrillation; CHF, congestive heart failure; CrCl, creatinine clearance; LVEF, left ventricular ejection fraction; NVAF, non-valvular atrial fibrillation; TIA, transient ischaemic attack. CHADS2-score is used to estimate stroke risk in patients with NVAF. * Or LVEF <40%. † For Xantus patients, figure related to only age >75 years old. ‡ For Xantus patients, this also could have included prior systemic embolism. ‖ 34.4% of patients had unknown CrCl values. ¶ Moderate to severe renal impairment was defined as CrCl <50 ml/min in Xantus. ** Xarelto is only approved for stroke prevention in NVAF patients with one or more risk factors.
PP-XAR-ALL-1818-1
References
- Camm J, et al. Eur Heart J. 2016;37:1145–1153. Camm J, et al. Eur Heart J. 2016;37:1145–1153. Return to content
- Patel MR, et al. N Engl J Med. 2011;365:883–891. Return to content
